10 Best Stocks Under $10 That Could Triple
On July 2, Dominic Pappalardo, Chief Multi-Asset Strategist at Morningstar Wealth, shared his views on small-cap stocks, which are projected to sustain their above-market performance as valuations stay...
Ars Pharmaceuticals Inc. (SPRY)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Levin Capital Strategies John A. Levin | 548,965 | $4,397,210 | -1% | 0.29% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.79 | 505,954 | $4,953,289.66 | 9,958,073 | 2024-03-27 | Filing | |
| $9.55 | 457,745 | $4,371,464.75 | 9,452,119 | 2024-03-26 | Filing | |
| $9.06 | 437,600 | $3,964,656.00 | 8,994,374 | 2024-03-25 | Filing | |
| $3.78 | 46,258 | $174,994.01 | 89,227 | 2023-09-29 | Filing | |
| $3.62 | 40,000 | $144,960.00 | 42,969 | 2023-09-28 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.00 | 25,000 | $250,000.00 | 12,176 | 2026-06-12 | Filing | |
| $10.00 | 3,355 | $33,550.00 | 90,910 | 2026-06-12 | Filing | |
| $8.71 | 21,828 | $190,049.85 | 10,789 | 2025-11-13 | Filing | |
| $8.86 | 136,380 | $1,208,790.49 | 0 | 2025-11-12 | Filing | |
| $8.91 | 30,000 | $267,357.00 | 136,380 | 2025-11-12 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,170,629 | $33,406,738 | 0.05% | |
| 2. | 1,133,046 | $9,075,698 | 0.54% | |
| 3. | 672,139 | $5,383,833 | 0.17% | |
| 4. | 471,856 | $3,779,567 | 0.21% | |
| 5. | 214,507 | $1,718,202 | 0.09% |
News See All
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q1 2026 Earnings Call Transcript
Operator: Good morning, and welcome to ARS Pharmaceuticals First Quarter 2026 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
Northland Highlights ARS Pharmaceuticals, Inc. (SPRY) Needle-Free Therapy as Major Innovation Driver
TheFly reported on April 9 that Northland initiated coverage of SPRY with an Outperform rating and a $25 price target.
10 Best Biotech Stocks Under $10 to Buy
According to Eli Casdin, CEO of Casdin Capital, biotech is currently experiencing a momentary stop despite being in one of the best economic environments in years.
12 Stocks that Will Bounce Back According to Wall Street Analysts
On January 5, Reuters reported that many analysts believe global investors will actively look for opportunities in undervalued areas of the financial markets in 2026.
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q3 2025 Earnings Call Transcript
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q3 2025 Earnings Call Transcript November 10, 2025ARS Pharmaceuticals, Inc. misses on earnings expectations.
ARS Pharmaceuticals, Inc. (SPRY): A Bull Case Theory
We came across a bullish thesis on ARS Pharmaceuticals, Inc. on Value Degen’s Substack’s Substack by Unemployed Value Degen. In this article, we will summarize the bulls’ thesis on SPRY.
ARS Pharmaceuticals (SPRY) Faces Patent Test as Lupin Files ANDA
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) is among the fastest growing small cap stocks to buy.
11 Fastest Growing Small Cap Stocks to Buy
These days, everyone is obsessed with speed: fast fashion, fast food, fast internet.
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q2 2025 Earnings Call Transcript
Operator: Good morning and welcome to the ARS Pharmaceuticals Conference Call. [Operator Instructions] Please be advised today's conference is being recorded.
Hedge Fund Resource Center